Durvalumab-Associated Hypopituitarism

Am J Ther. 2023 Nov-Dec;30(6):e583-e586. doi: 10.1097/MJT.0000000000001529. Epub 2022 Jun 15.

Authors

Olisaemeka Ogbue¹, Meghana Garisa¹, Muhammad Furqan¹, Sura Alqaisi¹, Rahul Patel²

Affiliations

¹ Department of Internal Medicine, Cleveland Clinic/Fairview Hospital, Cleveland, OH.
² Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, OH.

PMID: 37921684
DOI: 10.1097/MJT.0000000000001529

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / adverse effects
Chemoradiotherapy
Humans
Lung Neoplasms* / drug therapy

Substances

durvalumab
Antibodies, Monoclonal